Respiratory Distress Syndrome Clinical Trial
Official title:
Impact of Synchronized Nasal Intermittent Positive Pressure Ventilation Using Non Invasive Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants With Respiratory Distress
The nasal CPAP (continuous positive airway pressure), is a technique of noninvasive
ventilation commonly used in neonatal intensive care units, and has recently been used in
association with nasal intermittent mandatory ventilation (NIPPV - intermittent Nasal
Positive Pressure Ventilation), which consists of the application of respiratory positive
pressure cycles during the application of nasal CPAP, resulting in high pharyngeal
pressures. The NIPPV has advantages over traditional CPAP, including the prevention of
atelectasis, improved respiratory mechanics and decreased work of breathing in premature
infants. A refinement of this technique is the use of positive pressure breaths associated
with nasal CPAP synchronously in relation to the newborn's inspiratory effort (SNIPPV -
Synchronized Nasal Positive Pressure Ventilation).
Synchronization allows that the cycles of inspiratory positive pressure provided by the
ventilator coincide with the inspiratory effort, increasing the system efficacy. The
Neurally Adjusted Ventilatory Assist (NAVA) is a mode of partial ventilatory support based
on the use of electrical activity of the diaphragm (Edi) to control the mechanical
ventilator. The ventilatory assistance starts according to respiratory needs of the patient,
its use in very low birth weight infants showed an improvement in patient-ventilator
interaction, even in the presence of leak around the endotracheal tube. This prospective
randomized, clinical trial aims to evaluate, in preterm infants with gestational age lower
than 34 weeks with respiratory failure treated with noninvasive ventilatory support, the
impact of SNIPPV with neural adjustment (NAVA) on success ventilation and the need for
endotracheal intubation when compared to treatment with traditional CPAP.
Type and location of the study A prospective , randomized , open label clinical study will
be conducted at the Albert Einstein Jewish Hospital Neonatal ICU, after approval by the
Ethics Committee and the Research Institute of Education and Research. To participate in the
study the parents or legal guardians must complete and sign the Statement of Consent.
Randomization and formation of study groups Two study groups will be formed according to the
type of non- invasive ventilatory support: SNIPPV Group (synchronized nasal intermittent
positive pressure) and CPAP group (continuous positive airway pressure). The formation of
study groups will be by randomization through opaque envelopes containing in its interior
the type of treatment to be used. The envelopes will be opened at the initiation of
treatment.
Inclusion Criteria Will be included in study preterm infants with respiratory failure and
indication of noninvasive ventilatory support, characterized by clinical evidence of
respiratory failure requiring use of oxygen greater than or equal to a FiO2 0.25.
Exclusion Criteria Will be excluded from the study infants that parents did not agree on
participation; diagnosed with major congenital anomalies; with necessity of chest drainage;
diagnosis of intracranial hemorrhage grades III and IV according to the criteria of Papile
et al; persistence ductus arteriosus with hemodynamic consequences and diagnosis of severe
perinatal asphyxia - defined as less than 6 APGAR with 5 minutes of life.
Definition of the primary variable and secondary variables:
Demographic data regarding to birth weight, gestational age, sex, Apgar scores (1 and 5
minutes), type of delivery, use of antenatal corticosteroids, magnesium sulfate, multiple
births, maternal diseases will be collected.
The main variable will be the need for endotracheal intubation. This will be defined as the
need to use the fraction of inspired oxygen (FiO2) greater than 0.30 and 7 cmH2O or more of
CPAP pressure for maintaining a target oxygen saturation of 88-94 % for preterm infants with
gestational age less or equal to 27 6/7 weeks, or a FiO2 higher than 0.35 and 7 cmH2O or
more of CPAP pressure for maintaining a target oxygen saturation of 88-94 % for preterm
infants with gestational age higher or equal to 28 0/7 weeks gestation.
Secondary variables will be defined as the total time of nCPAP , the total time of oxygen
use; time for the indication of invasive mechanical ventilation, the incidence of
pneumothorax and the maximum values of FiO2 in noninvasive support, the average values of
CPAP pressure, the incidence of bronchopulmonary dysplasia (defined as oxygen requirement at
36 weeks corrected gestational age), the incidence of intracranial hemorrhage and
intracranial hemorrhage grades III and IV according to Papile et al.
Ventilatory strategies The equipment used for both ventilation modes will be the Servo i
(Maquet , Getinge Group , Solna , Sweden). The pressure initially applied will be CPAP 5
cmH2O in both groups and can be increased up to 7 cm H2O at the discretion of the attending
physician. The CPAP applied and FiO2 will be adjusted toward maintenance of oxygen
saturation target of 88-94 % .
Statistical analysis and sample size. Comparisons between continuous variables will be
performed by "t " Student test . The Kruskal - Wallys be used for non-parametric data .
Categorical variables were compared using the chi -square or Fisher's exact test , as
appropriate. The level of significance adopted will be 0.05.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06168149 -
The Relationship of Fetal Lung Elastography Values With the Development of Respiratory Distress in Cases of Preterm Labor
|
||
| Recruiting |
NCT03670732 -
CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure
|
N/A | |
| Recruiting |
NCT02901652 -
NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome
|
N/A | |
| Completed |
NCT02249143 -
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
|
N/A | |
| Suspended |
NCT01852916 -
NHFOV Versus NCPAP to Prevent Exubation Failure
|
N/A | |
| Completed |
NCT00208039 -
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
|
N/A | |
| Recruiting |
NCT03510169 -
Use of Gentle Synchronized Negative Pressure in Helping Babies Breathe
|
N/A | |
| Completed |
NCT00004494 -
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
|
Phase 1 | |
| Completed |
NCT00006058 -
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
|
N/A | |
| Completed |
NCT00004805 -
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
|
N/A | |
| Completed |
NCT03292562 -
A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation
|
N/A | |
| Completed |
NCT05948332 -
Definition and Management of Right Ventricular Injury in Adult Patients Receiving Extracorporeal Membrane Oxygenation
|
||
| Completed |
NCT05038514 -
The Effect of Music Therapy in COVID-19 Patients Given Prone Position
|
N/A | |
| Active, not recruiting |
NCT04079829 -
Postoperative Respiratory Abnormalities
|
||
| Completed |
NCT05462509 -
Feasibility of Use of the PATH bCPAP and Oxygen Blenders Device With Neonates in Uganda
|
N/A | |
| Active, not recruiting |
NCT03808402 -
The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS
|
||
| Completed |
NCT01812681 -
Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities
|
N/A | |
| Not yet recruiting |
NCT01440868 -
Sustained Lung Inflation in the Delivery Room in Preterm Infants at High Risk of Respiratory Distress Syndrome
|
N/A | |
| Completed |
NCT01517958 -
Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates
|
N/A | |
| Completed |
NCT01222247 -
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
|
Phase 3 |